Asymchem Laboratories (06821) announced that the group expects a net profit attributable to shareholders of the company of approximately RMB 0.48 billion yuan to RMB 0.55 billion yuan for the reporting period from January 1, 2024 to June 30, 2024, a year-on-year decrease of approximately 67.39% to 71.54%.
In the first half of 2024, the company achieved revenue of approximately RMB 2.66 billion yuan to RMB 2.74 billion yuan, a year-on-year decrease of 40.72% to 42.45%, mainly due to the delivery of a substantial order in the same period last year and no relevant orders this year. During the reporting period, amid the persistently low financing environment for biomedical industries both domestically and internationally, the company's revenue achieved a slight growth if the impact of the substantial order in the same period last year is excluded, and the CDMO business of small-molecule drugs still maintained positive growth after excluding the impact of the substantial order. However, emerging business revenue decreased year-on-year due to the unsatisfactory recovery of domestic biomedical financing.